Bayer and Gilead expand in manufacturing
pharmafile | June 2, 2015 | News story | Manufacturing and Production, Sales and Marketing | Bayer, Gilead, brett wells, manufacturing
Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and Canada.
German-based Bayer says it will be able to export to at least 50 countries over the next three years as demand from overseas markets lifts. Helping this along will be the shelling out of $3.4 million to expand its Indonesian production capacity for effervescents in 2015.
Bayer’s Indonesia unit has spent around $8.8 million since early last year to expand its warehousing and production capacity, and now a new warehouse is located at its large facility in Depok – to accommodate all its pharma production.
“The new facility is expected to start production next year,” Bayer Indonesia president director Ashraf Al-Ouf told The Jakarta Post.
Meanwhile Gilead Sciences is planning to invest $100 million into the expansion of its Edmonton plant in Canada. The US hep C specialist pharma giant opened the first of two new buildings at its Canadian facility just last week.
Dr Robin Nicol who is the vice president of chemical operations and general manager of Gilead Alberta, says: “This is just the first step, there’s lots more to come. This is a great opportunity to significantly expand our capacity here in Edmonton and to make drugs across many different therapeutic areas including HIV, cancer, liver disease, and cardiovascular.”
Expected to be completed in 2017, the expansion will include a new manufacturing building and a processing tower that will contain spray drying technology that provides improved absorption for pharmaceuticals, the firm told the Edmonton Sun.
The construction of a second building is underway with completion slated for the spring of next year, and when all the planned expansions are completed, the facility will total 184,000 sq.ft. Gilead said it expects to hire an additional 170 people over the next two years as a result.
Brett Wells
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
